# Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients

> **NCT07132684** · PHASE3 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 240 (estimated)

## Conditions studied

- AML, Adult

## Interventions

- **DRUG:** Daunorubicin/Idarubicin
- **DRUG:** Cytarabine
- **DRUG:** Azacitidine
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT07132684
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-31
- **Primary completion:** 2027-08-30
- **Final completion:** 2028-08-30
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07132684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07132684, "Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07132684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*